News on lab-developed tests and emerging diagnostic technologies.
Cepheid Nabs CE-IVD Mark for Molecular NPM1 Mutation Test for AML Monitoring
The test quantifies mutant NPM1 mRNA transcripts in peripheral blood specimens from patients with acute myeloid leukemia.
New Bladder Cancer Molecular Classification Predicts Response to Common Immunotherapy
The new subtypes could help clinicians pick alternative therapies for patients unlikely to respond to Bacillus Calmette-Guérin treatment.
Using Arima's technology, NYU researchers were able to identify a novel rearrangement in the PDL-1 gene in a pediatric brain tumor, which led to treatment with immunotherapy.
Freenome Acquires Cancer Dx Firm Oncimmune
Oncimmune offers its CE-marked EarlyCDT Lung blood test, an autoantibody platform, and a research and development pipeline of more than seven cancer detection signatures.
Genetic Testing Challenges in Oncology: Patient Insists on Unnecessary Von Hippel-Lindau Testing
A patient with various health concerns insists on VHL genetic testing after a doctor suggests her symptoms seem to fit those caused by the inherited condition.